MoonLake Immunotherapeutics has entered into an agreement with Hercules Capital to provide up to $500 million in non-dilutive funding. This strengthens the company’s financial position and secures resources to further develop Sonelokimab, a therapeutic candidate targeting inflammatory diseases.
Under the agreement, MoonLake has received an initial tranche of $75 million, with subsequent disbursements tied to the achievement of specific clinical milestones. These funds complement the company’s existing $448 million cash balance, ensuring financial stability on the path toward Sonelokimab’s expected launch in 2027.
Sonelokimab is a humanized nanobody (~40 kDa) capable of penetrating inflamed tissues and inhibiting IL-17A/A, IL-17A/F, and IL-17F/F dimers. The drug is currently undergoing Phase II and III clinical trials, including the VELA program for treating hidradenitis suppurativa (HS), with results expected by mid-2025.
MoonLake’s CFO, Matthias Bodenstedt, emphasized that this financing strengthens the company’s position without diluting existing shareholders’ stakes.
To discuss the agreement details and provide clinical updates, the company will host a Capital Markets Update event on April 29, 2025, in New York.
🔗 More info: MoonLake Press Release
